Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal bupivacaine (OhioHealth)
- Development stage
- Unknown
- Lead developer
- OhioHealth
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Infiltration, Perineural
01
Overview
Liposomal bupivacaine is an extended-release formulation of the amide-type local anesthetic bupivacaine, utilizing the DepoFoam multivesicular liposome technology. This delivery system allows for the slow, controlled release of bupivacaine over an extended period, typically providing analgesia for up to 72 hours following a single administration. It is primarily indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block for postsurgical regional analgesia. By extending the duration of pain relief, liposomal bupivacaine is often used as part of a multimodal, opioid-sparing analgesic regimen. In clinical studies sponsored by OhioHealth, it has been evaluated for its efficacy in managing postoperative pain following total knee arthroplasty (TKA) compared to standard multimodal analgesic protocols.
- Brand names
- Exparel
- Other names
- Bupivacaine liposome injectable suspensionLiposomal bupivacaine-OhioHealth
02
Targets
KATP channel (ATP-sensitive potassium channel)NMDAR (Glutamate receptor ionotropic, NMDA)SCN5A (Sodium channel protein type 5 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on liposomal bupivacaine (OhioHealth).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal bupivacaine (OhioHealth).